chr4-123028280-G-A
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The ENST00000274008.5(AFG2A):c.1964G>A(p.Arg655Gln) variant causes a missense change. The variant allele was found at a frequency of 0.000906 in 1,614,112 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R655G) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000274008.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SPATA5 | NM_145207.3 | c.1964G>A | p.Arg655Gln | missense_variant | 11/16 | ENST00000274008.5 | NP_660208.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AFG2A | ENST00000274008.5 | c.1964G>A | p.Arg655Gln | missense_variant | 11/16 | 1 | NM_145207.3 | ENSP00000274008 | P1 | |
AFG2A | ENST00000422835.2 | n.2006G>A | non_coding_transcript_exon_variant | 11/15 | 1 | |||||
AFG2A | ENST00000675612.1 | c.2033G>A | p.Arg678Gln | missense_variant | 12/17 | ENSP00000502453 |
Frequencies
GnomAD3 genomes AF: 0.000605 AC: 92AN: 152156Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000581 AC: 146AN: 251440Hom.: 0 AF XY: 0.000596 AC XY: 81AN XY: 135898
GnomAD4 exome AF: 0.000937 AC: 1370AN: 1461838Hom.: 6 Cov.: 32 AF XY: 0.000928 AC XY: 675AN XY: 727222
GnomAD4 genome AF: 0.000604 AC: 92AN: 152274Hom.: 0 Cov.: 32 AF XY: 0.000658 AC XY: 49AN XY: 74468
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 17, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jan 24, 2018 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 26, 2024 | Observed in homozygous state in a patient with white matter disease in the literature (PMID: 35012964); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 35012964) - |
Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Dec 07, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 27, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 655 of the SPATA5 protein (p.Arg655Gln). This variant is present in population databases (rs147873489, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with SPATA5-related conditions. ClinVar contains an entry for this variant (Variation ID: 203526). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 12, 2024 | Variant summary: SPATA5 c.1964G>A (p.Arg655Gln) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00058 in 251440 control chromosomes (gnomAD). c.1964G>A has been reported in the literature in an individual affected with white matter disorder (Schluter_2022). This report does not provide unequivocal conclusions about association of the variant with Epilepsy, Hearing Loss, And Mental Retardation Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 35012964). ClinVar contains an entry for this variant (Variation ID: 203526). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at